ClinicalTrials.gg
Active, not recruitingNCT06816368DUAL-VTUpdated Oct 20, 2026

Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia

An interventional study of Catheter ablation using sequential radiofrequency and pulsed field ablation in Ventricular Tachycardia (V-Tach), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Active, not recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Planned enrollment
26th of 39
30 · median 130
Started
2025
with 4 others
No phase
19 of 54
8 open now
Primary completion
2026-09
later than 3 of 18 live
Registered
48th of 54
by date
Lead sponsor
2 of 54
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 26th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2025, is one of 19 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 48th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

This will be a single arm study evaluating a new ablation technology for performing catheter ablation of ventricular tachycardia. The technology combines novel pulsed field ablation with radiofrequency ablation.

Read the detailed description

One of the limitations of conventional ventricular tachycardia (VT) ablation using radiofrequency (RF) energy is the inability to reach arrhythmogenic tissue deep in the myocardium. Pulsed field (PF) energy, which causes cell death via irreversible electroporation and is non-thermal, may improve outcomes in patients with VT since it has been shown to have better depth penetration in previously scarred tissue. Furthermore, the combination of RF and PF treatment in the same location can increase tissue lesion depth more than either energy alone. This can potentially minimize the need for epicardial ablations, or complex bipolar ablation strategies as well as associated procedural complications. RF and PF have been used extensively for atrial ablation. RF has been the mainstay for all VT ablation but PF use for VT is relatively new.

Pre-clinical work of ventricular ablation procedures in a swine model evaluated the effects of combined and co-localized PF and RF application on cardiac lesion size and their corresponding histological changes. Compared to PF alone ablation, lesion depths and widths were significantly greater in both RF-PF and PF-RF applications. Histology for both combined lesions showed central thermal necrosis surrounded by a hemorrhagic and transitional PF zone. The findings provided evidence for appropriate use of combination therapy in clinical settings.

The design of the study will be carried out as an interventional, prospective, multicenter, single-arm safety and effectiveness evaluation using the Biosense Webster PF/RF Ablation System. The study will enroll subjects with sustained symptomatic VT who are candidates for catheter ablation. Eligible subjects who sign the Informed Consent Form (ICF) and who meet all eligibility criteria will be enrolled and treated with the STSF Catheter in conjunction with the TRUPULSE™ Generator. A maximum sample size of 30 subjects is planned in the study. All study subjects will be followed-up for 6 months after the study procedure.

03

Conditions studied

  • Ventricular Tachycardia (V-Tach)

Keywords

  • ventricular tachycardia
  • pulsed field ablation
  • radiofrequency
  • combined dual energy
  • catheter ablation
  • pilot study
  • human
  • clinical trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with two or more documented spontaneous episodes of sustained symptomatic VT within 3 months or 1 sustained episode of VT or VT storm (two or more VTs in 24 hours) which required device therapy (shock or anti-tachycardia pacing), external cardioversion, escalated antiarrhythmic therapy, and / or hospitalization

    • Documented episodes assessment will be performed by a review of ECGs, hospitalization records, and/or Implantable Cardioverter Defibrillator (ICD) interrogation
    • Patients must have an ICD implanted
  2. Age ≥18 years
  3. ≥ 30% as estimated by echocardiography, contrast ventriculography, radionuclide imaging or cardiac magnetic resonance imaging within the previous 30 days.
  4. Willing and capable of understanding the objective, risk, and requirement of the study, and providing consent.
  5. Able and willing to comply with all pre-, post- and follow-up testing and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Definite protruding LV thrombus on pre-ablation imaging.
  2. Myocardial infarction (MI) within the preceding 2 months. Patients with incessant VT (present 50% of the time with intervention for a period >12 hrs) may be enrolled if their MI is at least 3 weeks old.
  3. Absence of vascular access to the heart chambers.
  4. Other disease process likely to limit survival to less than 6 months.
  5. Class IV heart failure.
  6. Serum creatinine of ≥ 2.5 mg/dl (221 umol/L).
  7. Thrombocytopenia (\< 50 x 109/L) or coagulopathy.
  8. to heparin.
  9. Women who are pregnant.
  10. Cardiac surgery (i.e. ventriculotomy, atriotomy) within the past 2 months. Patients with incessant VT may be enrolled if their surgery is at least 3 weeks old.
  11. Acute illness or active systemic infection.
  12. Severe aortic stenosis or flail mitral valve.
  13. Uncontrolled heart failure.
  14. Significant congenital anomaly or medical problem that in the opinion of the principal Investigator would preclude enrollment in the study.
  15. Enrolled in an study evaluating another device or drug.
  16. Unwilling to participate in the study or unavailable for follow up visits.
  17. Previous VT ablation within a year.
  18. Epicardial mapping or ablation is anticipated or planned before the VT ablation procedure.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ablation group

    Patients in this single arm will all undergo clinically-indicated catheter ablation of ventricular tachycardia using a novel combination ablation device capable of delivering both radiofrequency and pulsed field ablation.

    Device: Catheter ablation using sequential radiofrequency and pulsed field ablation

Interventions

  • DeviceCatheter ablation using sequential radiofrequency and pulsed field ablation

    We are using sequential application of radiofrequency and pulsed field ablation to increase lesion depth and better treat ventricular arrhythmias.

06

What researchers measure

Primary outcomes

  1. Acute procedural success (elimination of all clinically relevant ventricular tachycardias)

    Elimination of all clinically relevant ventricular tachycardias at the end of the procedure.

    Time frame: 6 months

  2. Primary Safety Outcome

    Primary adverse events (PAE) within 7 days after ablation

    Time frame: From ablation procedure until 7 days post-ablation

Secondary outcomes

  1. Freedom from ventricular tachycardia recurrence at 6 months post-ablation

    Freedom from recurrence (symptomatic or asymptomatic) of monomorphic VT that was targeted at ablation at 6 months following the ablation procedure, plus additional failure modes including acute procedural failure, repeat ablation failure, non-study device failure, AAD failure

    Time frame: From ablation until 6 months post-ablation

  2. Secondary safety outcome

    Primary adverse events at 7 days - 6 months after ablation

    Time frame: From 7 days until 6 months post-ablation

Other outcomes

  1. Quality of life using ICDC score

    Quality of life using the ICDC quality of life score. There are 20 questions each ranked on a Likert scale from 0 to 4. Points are given for number of questions showing any concern and the degree of concern for a total of 100 points.

    Time frame: 6 months post-ablation

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — All relevant data will be published at study end in final manuscript. This is a small, pilot, first-in-human study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Sep 2026, 14 months.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's 14 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2026 → Sep 2026 and completion Aug 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Feb 10, 2025
StartActual
Jul 28, 2025
Primary completionActual
Sep 30, 2026was Jul 2026
CompletionEst.
Jan 2027was Aug 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Sep 30, 2026 (actual)
Oct 20, 2026
Study completion
Aug 2026→Jan 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Jul 2026→Sep 30, 2026 (now actual)
    Study completion Aug 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06816368
Responsible party
Atul Verma (Director of Cardiology, Principal Investigator, Professor of Medicine, McGill University, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Feb 10, 2025
Start date
Jul 28, 2025
Primary completion
Sep 30, 2026
Completion
Jan 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Atul Verma, MD
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion